When it comes to the creation and production of bispecific antibodies (BsAbs), Creative Biolabs is without a doubt a pioneer. We provide highly repeatable NK cell complement-dependent cytotoxicity (CDC) assays for the evaluation and interpretation of the cytotoxic effects of your BsAbs thanks to our team of experienced scientists and years of expertise. We can quickly and efficiently assess the cytotoxicity profile of your treatment candidates using our full-scale antibody analysis technology in a high throughput way.

A promising anti-cancer treatment that targets antigens primarily expressed in tumor cells to increase the therapy's specificity is the development of antibody therapy. Antibodies that target TAA have the ability to trigger the body's own defense mechanisms against tumors, including CDC. Even after chemotherapy, CDC is highly preserved and essential for the therapeutic antibodies' best functioning. Nevertheless, not all antibodies produce this activity. Some do.